logo-loader

Open Orphan: Sustaining commercial traction

Published: 08:04 16 Nov 2020 EST

Proactive analyst Emma Ulker talks to Proactive London about Open Orphan (LON:ORPH).

Ulker talks through the prospects for the specialist pharmaceutical services company, which is the world leader in the testing of vaccines and antivirals using human challenge studies.

Ulker believes Open Orphan continues to make excellent progress towards maximising the capacity utilisation of its unique clinical facilities and services capabilities.

She believes the investment case centres on continuing to leverage its differentiated portfolio of assets and services, including converting a sales pipeline of non-COVID-19 related services worth over £110m.

Click here to read Proactive Analyst Emma Ulker's latest update

Poolbeg Pharma chair discusses shift to executive role; hVIVO share sale

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) chairman Cathal Friel joined Proactive's Stephen Gunnion to discuss his new hands-on role at the company. Stepping up as the executive chairman at Poolbeg Pharma, Friel expressed his intention to replicate the success he achieved with hVIVO, another...

on 02/15/2024